Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2025)

InMed Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.51 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 85.99% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$3.32, up 75.57%, while the annual FY2025 figure was -$8.36, 58.49% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.51 in Q4 2025 per INM's latest filing, down from -$0.44 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.14 in Q2 2023 to a low of -$15.24 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$3.51, with a median of -$3.14 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 2562.39% in 2024, then surged 88.25% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$6.14 in 2022, then skyrocketed by 39.58% to -$3.71 in 2023, then increased by 1.89% to -$3.64 in 2024, then soared by 85.99% to -$0.51 in 2025.
  • Per Business Quant, the three most recent readings for INM's EPS (Weighted Average and Diluted) are -$0.51 (Q4 2025), -$0.44 (Q3 2025), and -$0.43 (Q2 2025).